Key TakeawaysODAC’s recommendation supports the use of PD-1 inhibitors, including BeiGene’s TEVIMBRA®, for esophageal squamous cell carcinoma and gastric cancers, but only in...
Lung Cancer Treatment Advanced with European Commission Approval of BeiGene’s Tislelizumab
BeiGene, Ltd., a pioneering global oncology company, announced today that the European Commission (EC) has granted approval for the use of tislelizumab as a...
